Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IDT combines with 454 in worldwide primer pact

This article was originally published in Clinica

Executive Summary

Roche’s DNA sequencing subsidiary 454 Life Sciences has signed an exclusive co-promotional agreement with nucleic acids specialist Integrated DNA Technologies (IDT). The deal, of which specific financial details were not revealed, will see Coralville, Iowa-based IDT use its online design tool to design, synthesize and purify fusion primers for certain 454 sequencing applications. These applications include sequencing technology for the detection of low-frequency mutations in disease-associated genes, and identification and quantification of common and rare variants within a population.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel